Moreton Paul, Hillmen Peter
Haematological Malignancy Diagnostic Service, University of Leeds, UK.
Semin Oncol. 2003 Aug;30(4):493-501. doi: 10.1016/s0093-7754(03)00253-7.
Alemtuzumab (Campath-1H, Ilex Pharmaceuticals, San Antonio, TX) is a humanized monoclonal antibody that recognizes the CD52 antigen expressed on malignant and normal B lymphocytes. It has come to be used therapeutically in B-cell malignancies. Responses are seen in non-Hodgkin's lymphoma (NHL), and alemtuzumab can induce molecular remissions in relapsed chronic lymphocytic leukaemia (CLL), even when refractory to purine analogues. Most studies reveal the responses to be superior in the absence of bulky disease. Infusion-related side effects such as rigors, hypotension, and nausea are reduced by using the subcutaneous route of administration. Infectious complications are the most important toxicity seen and are related to the depletion of normal lymphocytes. The clinical efficacy in combination with both fludarabine and rituximab is under investigation.
阿仑单抗（Campath-1H，Ilex制药公司，得克萨斯州圣安东尼奥）是一种人源化单克隆抗体，可识别恶性和正常B淋巴细胞上表达的CD52抗原。它已被用于B细胞恶性肿瘤的治疗。在非霍奇金淋巴瘤（NHL）中可见疗效，阿仑单抗可诱导复发的慢性淋巴细胞白血病（CLL）发生分子缓解，即使对嘌呤类似物耐药时也如此。大多数研究表明，在无大块病灶的情况下疗效更佳。通过皮下给药途径可减少诸如寒战、低血压和恶心等与输注相关的副作用。感染性并发症是最主要的毒性反应，与正常淋巴细胞耗竭有关。阿仑单抗与氟达拉滨和利妥昔单抗联合使用的临床疗效正在研究中。
